ASCO 2017 – Multiple Myeloma

This phase 3 study compared lenalidomide maintenance versus placebo after stem-cell transplant in patients with newly diagnosed multiple myeloma, adjusting overall survival (OS) and progression-free survival (PFS) for treatment crossover. Read More ›

Insights from the Connect MM Registry show that lenalidomide maintenance therapy after autologous stem-cell transplant (ASCT) significantly improves progression-free survival and overall survival in patients with newly diagnosed multiple myeloma (NDMM). Read More ›

An update on the POLLUX study has shown that daratumumab, lenalidomide, and dexamethasone improves efficacy outcomes in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

The 4-year follow-up of the ELOQUENT-2 study examining elotuzumab plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) shows sustained safety and efficacy results. Read More ›

Researchers from the CASTOR trial provided an update on the efficacy and safety of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

This study examined the trends in survival and healthcare costs of US patients with multiple myeloma from 2006 to 2014. Read More ›

A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse. Read More ›

This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma. Read More ›

The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM). Read More ›